265 related articles for article (PubMed ID: 33162471)
21. A Case of acromegaly associated with subclinical Cushing's disease.
Tsuchiya K; Ohta K; Yoshimoto T; Doi M; Izumiyama H; Hirata Y
Endocr J; 2006 Oct; 53(5):679-85. PubMed ID: 16926523
[TBL] [Abstract][Full Text] [Related]
22. Effects of anti-somatostatin agents on glucose metabolism.
Vergès B
Diabetes Metab; 2017 Oct; 43(5):411-415. PubMed ID: 28579289
[TBL] [Abstract][Full Text] [Related]
23. The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.
Simeoli C; Auriemma RS; Tortora F; De Leo M; Iacuaniello D; Cozzolino A; De Martino MC; Pivonello C; Mainolfi CG; Rossi R; Cirillo S; Colao A; Pivonello R
Endocrine; 2015 Dec; 50(3):725-40. PubMed ID: 25743263
[TBL] [Abstract][Full Text] [Related]
24. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.
Shimon I; Rot L; Inbar E
Pituitary; 2012 Dec; 15(4):608-13. PubMed ID: 22918543
[TBL] [Abstract][Full Text] [Related]
25. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
Katznelson L
J Clin Endocrinol Metab; 2013 May; 98(5):1803-7. PubMed ID: 23539733
[TBL] [Abstract][Full Text] [Related]
26. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.
Colao A; De Block C; Gaztambide MS; Kumar S; Seufert J; Casanueva FF
Pituitary; 2014 Apr; 17(2):180-6. PubMed ID: 23564338
[TBL] [Abstract][Full Text] [Related]
27. Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.
Mizuno T; Inoshita N; Fukuhara N; Tatsushima K; Takeshita A; Yamada S; Nishioka H; Takeuchi Y
Intern Med; 2022 Mar; 61(5):679-685. PubMed ID: 34471015
[TBL] [Abstract][Full Text] [Related]
28. The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.
Trementino L; Zilio M; Marcelli G; Michetti G; Barbot M; Ceccato F; Boscaro M; Scaroni C; Arnaldi G
Endocrine; 2015 Sep; 50(1):154-61. PubMed ID: 25500791
[TBL] [Abstract][Full Text] [Related]
29. A prospective longitudinal study of Pasireotide in Nelson's syndrome.
Daniel E; Debono M; Caunt S; Girio-Fragkoulakis C; Walters SJ; Akker SA; Grossman AB; Trainer PJ; Newell-Price J
Pituitary; 2018 Jun; 21(3):247-255. PubMed ID: 29313180
[TBL] [Abstract][Full Text] [Related]
30. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
31. Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.
Samson SL
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):445-50. PubMed ID: 25003365
[TBL] [Abstract][Full Text] [Related]
32. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
[TBL] [Abstract][Full Text] [Related]
33. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
34. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
37. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Boscaro M; Bertherat J; Findling J; Fleseriu M; Atkinson AB; Petersenn S; Schopohl J; Snyder P; Hughes G; Trovato A; Hu K; Maldonado M; Biller BM
Pituitary; 2014 Aug; 17(4):320-6. PubMed ID: 23943009
[TBL] [Abstract][Full Text] [Related]
38. Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches.
Lovato CM; Kapsner PL
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29925553
[TBL] [Abstract][Full Text] [Related]
39. A somatotropin-producing pituitary adenoma with an isolated adrenocorticotropin-producing pituitary adenoma in a female patient with acromegaly, subclinical Cushing's disease and a left adrenal tumor.
Kobayashi Y; Takei M; Ohkubo Y; Kakizawa Y; Matoba H; Kumagai M; Takeda T; Suzuki S; Komatsu M
Endocr J; 2014; 61(6):589-95. PubMed ID: 24705560
[TBL] [Abstract][Full Text] [Related]
40. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
